These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15510992)

  • 1. Meeting report: Breast cancer in the older woman.
    Martoni A; Cucinotta D; Balducci L
    Tumori; 2004; 90(4):437-45. PubMed ID: 15510992
    [No Abstract]   [Full Text] [Related]  

  • 2. Early breast cancer in the older woman.
    VanderWalde A; Hurria A
    Clin Geriatr Med; 2012 Feb; 28(1):73-91. PubMed ID: 22326036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of cancer of the breast in the elderly.
    Ashkanani F; Eremin O; Heys SD
    Eur J Surg Oncol; 1998 Oct; 24(5):396-402. PubMed ID: 9800967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early breast cancer in the elderly: assessment and management considerations.
    Albrand G; Terret C
    Drugs Aging; 2008; 25(1):35-45. PubMed ID: 18184027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Modeling of Surgery Plus Adjuvant Endocrine Therapy Versus Primary Endocrine Therapy Alone in UK Women Aged 70 and Over With Early Breast Cancer.
    Holmes GR; Ward SE; Brennan A; Bradburn M; Morgan JL; Reed MWR; Richards P; Rafia R; Wyld L;
    Value Health; 2021 Jun; 24(6):770-779. PubMed ID: 34119074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
    Muss HB; Woolf S; Berry D; Cirrincione C; Weiss RB; Budman D; Wood WC; Henderson IC; Hudis C; Winer E; Cohen H; Wheeler J; Norton L;
    JAMA; 2005 Mar; 293(9):1073-81. PubMed ID: 15741529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
    Norum J
    Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geriatric assessment tool application in treatment recommendations for older women with breast cancer.
    Munir A; Huws A; Khan S; Sharaiha Y; Holt S; Khawaja S
    Breast; 2022 Jun; 63():101-107. PubMed ID: 35366503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment for older women with invasive breast cancer.
    Jolly TA; Williams GR; Bushan S; Pergolotti M; Nyrop KA; Jones EL; Muss HB
    Womens Health (Lond); 2016 Jan; 12(1):129-45; quiz 145-6. PubMed ID: 26767315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
    Barthélémy P; Heitz D; Mathelin C; Polesi H; Asmane I; Litique V; Rob L; Bergerat JP; Kurtz JE
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):196-204. PubMed ID: 20655243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
    Ward MC; Vicini F; Al-Hilli Z; Chadha M; Pierce L; Recht A; Hayman J; Thaker N; Khan AJ; Keisch M; Shah C
    Breast Cancer Res Treat; 2020 Jul; 182(2):355-365. PubMed ID: 32468336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.
    Desch CE; Hillner BE; Smith TJ; Retchin SM
    J Clin Oncol; 1993 Apr; 11(4):777-82. PubMed ID: 8478671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional status decline in older patients with breast and colorectal cancer after cancer treatment: A prospective cohort study.
    van Abbema D; van Vuuren A; van den Berkmortel F; van den Akker M; Deckx L; Buntinx F; van Kampen R; Lambooij E; de Boer M; de Vos-Geelen J; Tjan-Heijnen VC
    J Geriatr Oncol; 2017 May; 8(3):176-184. PubMed ID: 28159513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic adjuvant therapy of breast cancer.
    Garrett TJ; Vahdat LT; Kinne DW
    J Surg Oncol; 1997 Feb; 64(2):167-72. PubMed ID: 9047258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 19. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
    Younis T; Skedgel C
    Pharmacoeconomics; 2011 May; 29(5):361-5. PubMed ID: 21504237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.